BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, and China, that involves near-term payments of $90 million with another ...
Being a working professional and preparing for CAT was not easy. I had to pull all-nighters, wake up early and attend classes. I gave at least 6-8 hours every day to CAT preparation,” she said. With ...
After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with cuts in numerous countries. Now, hundreds of employees in Switzerland are due ...
Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...
Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. In fact, Zealand is ...
Wegovy Weight-Loss Pills Are Now Available in the U.S.—Here’s What That Means The first GLP-1 pills for weight loss are ...
Bristol Myers Squibb has been named industry company of the year at the Pharma Industry Awards 2025 in recognition of its excellence, innovation, and leadership within Ireland’s pharma sector. The ...
Two absolutes in harmonising with nature as awareness sparks interest – Literacy drives change Hazards teach lessons to ...
Newspoint on MSN
RRB Group D: Understand the Group D syllabus and exam pattern thoroughly; registration for 22,000 posts will begin in January.
The Railway Recruitment Board has released the notification for Group D Level-1 recruitment. Registration for 22,000 posts is ...
Although children can sleep well, most adults have trouble getting a good night’s sleep. They go to bed each night, but find ...
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model, BALANCE, for Medicare Part D and ...
As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. Seattle’s Adaptive Biotechnologies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback